Literature DB >> 9484494

Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents.

S K Meegalla1, K Plössl, M P Kung, D A Stevenson, M Mu, S Kushner, L M Liable-Sands, A L Rheingold, H F Kung.   

Abstract

Recently, we reported the first human study of [99mTc]TRODAT-1, technetium, 2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2- yl]methyl](2-mercaptoethyl)amino]ethyl]amino]-ethanethiolato(3-)-o xo- [1R-(exo-exo)]-, as an imaging agent of central nervous system (CNS) dopamine transporters. Due to the existence of several chiral centers on this molecule, upon the formation of [99mTc]TRODAT-1 complex (2) several diastereomers could be created. Two major diastereomers of [99mTc]TRODAT-1 (2), designated as peak A (2A) and peak B (2B), were separated by HPLC. Biodistribution of the purified diastereomers 2A,B was evaluated in rats. It appears that 2A displayed a higher lipophilicity than 2B (PC = 305 and 229, respectively), and a similar trend was observed for the initial brain uptake at 2 min postinjection (0.50% and 0.28% dose/organ for 2A,B, respectively). At 60 min post-iv-injection, the specific uptakes, as measured by [striatum - cerebellum]/cerebellum ([ST-CB]/CB) ratio, were 1.72 and 2.79 for 2A,B, respectively. The higher [ST-CB]/CB ratio observed for 2B was corroborated by the results of an in vitro binding assay. Higher binding affinity for dopamine transporters was observed for 3B (Ki = 13.87 and 8.42 nM for the analogous rhenium complexes 3A,B, respectively). The structure of the [99mTc]TRODAT-1 complexes was deduced using nonradioactive rhenium as a surrogate for radioactive technetium complex. Reacting free TRODAT-1 ligand with [Bu4N][ReOCl4] yielded two major complexes: Re-TRODAT-1A (3A) and Re-TRODAT-1B (3B) (corresponding with peaks A and B of [99mTc]TRODAT-1, respectively), whose structures were determined by X-ray analysis. The X-ray structures show that both complexes have a pseudo-square-pyramidal structure of [RevO]3+N2S2 core with oxygen occupying the apical position and the N-alkyl substitution in syn-configuration to the oxo-rhenium bond. In conclusion, TRODAT-1 formed at least two diastereomers after complexing with a metal(V)-oxo (M = 99mTc, Re) center core. The two isomers display different binding affinities toward dopamine transporters and distinct properties of localization in the striatum area of the brain where the transporters are located.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484494     DOI: 10.1021/jm970742b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.

Authors:  G J E Schmitt; T Frodl; S Dresel; C la Fougère; R Bottlender; N Koutsouleris; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-15       Impact factor: 5.270

2.  Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.

Authors:  G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-13       Impact factor: 5.270

3.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.

Authors:  Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

4.  Zn Complex of Diaminedithiol Tetradentate Ligand as a Stable Precursor for 99mTc-Labeled Compounds.

Authors:  Shinobu Oshikiri; Tomoya Uehara; Hiroyuki Suzuki; Miho Koike-Satake; Akihiro Hino; Yasushi Arano
Journal:  Molecules       Date:  2020-01-08       Impact factor: 4.411

5.  Synthesis, Radiolabeling, and Preliminary in vivo Evaluation of [68Ga] IPCAT-NOTA as an Imaging Agent for Dopamine Transporter.

Authors:  Shiou-Shiow Farn; Kang-Wei Chang; Wan-Chi Lin; Hung-Man Yu; Kun-Liang Lin; Yu-Chin Tseng; Yu Chang; Chung-Shan Yu; Wuu-Jyh Lin
Journal:  Drug Des Devel Ther       Date:  2021-06-17       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.